120 related articles for article (PubMed ID: 36496349)
1. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Jeong SI; Kim Y; Nah JJ; Huh W; Jang IJ; Hwang JG; Lee S
Br J Clin Pharmacol; 2023 Jun; 89(6):1780-1788. PubMed ID: 36496349
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
Kim B; Huh KY; Hwang JG; Nah J; Huh W; Cho JM; Jang IJ; Yu KS; Kim Y; Lee S
Br J Clin Pharmacol; 2023 Apr; 89(4):1462-1470. PubMed ID: 36422809
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects.
Yoon S; Park MS; Jin BH; Shin H; Na J; Huh W; Kim CO
Expert Opin Drug Metab Toxicol; 2023; 19(7):479-485. PubMed ID: 37593838
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.
Hwang JG; Lee S; Huh W; Han J; Oh J; Jang IJ; Yu KS
Br J Clin Pharmacol; 2022 Sep; 88(9):4100-4110. PubMed ID: 35395697
[TBL] [Abstract][Full Text] [Related]
5. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Cho YS; Lee SH; Lim HS; Bae KS
J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
[TBL] [Abstract][Full Text] [Related]
9. Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
An JH; Choi HS; Choi JS; Lim HW; Huh W; Oh YI; Park JS; Han J; Lim S; Lim CY; Kim TH; Moon JB; Youn HY
Vet Med Sci; 2024 May; 10(3):e1454. PubMed ID: 38686463
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Lee SW; Park SI; Lee S; Chung JY; Yu KS
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Yang E; Yoo H; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():651-658. PubMed ID: 33628012
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects.
Jin X; Kim E; Huh KY; Hwang I; Cho JY; Yu KS; Lee S
Transl Clin Pharmacol; 2020 Mar; 28(1):43-54. PubMed ID: 32274380
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Choi HY; Lim HS; Kim YH; Jeon HS; Kim MJ; Lee SH; Jung JH; Lee YK; Kim HJ; Bae KS
Curr Med Res Opin; 2015 Feb; 31(2):229-41. PubMed ID: 25350224
[TBL] [Abstract][Full Text] [Related]
14. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Jeong SI; Ban MS; Hwang JG; Park MK; Lim S; Kim S; Kwon SK; Kim Y; Cho JM; Na JJ; Huh W; Chung JY
Diabetes Obes Metab; 2024 Jul; 26(7):2588-2597. PubMed ID: 38618974
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
16. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
17. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
20. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]